Alkermes gets a mid-stage narcolepsy hit, but trails Takeda in R&D race

Alkermes’ narcolepsy therapy improved the ability of patients in a mid-stage trial to stay awake, the company said Monday. And while a Phase 3 program is on the cards, it said ...